Denali Therapeutics Management
Management criteria checks 4/4
Denali Therapeutics' CEO is Ryan Watts, appointed in Aug 2015, has a tenure of 9.25 years. total yearly compensation is $7.88M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 1.56% of the company’s shares, worth $54.91M. The average tenure of the management team and the board of directors is 5.8 years and 8.1 years respectively.
Key information
Ryan Watts
Chief executive officer
US$7.9m
Total compensation
| CEO salary percentage | 8.5% |
| CEO tenure | 9.3yrs |
| CEO ownership | 1.6% |
| Management average tenure | 5.8yrs |
| Board average tenure | 8.1yrs |
Recent management updates
Recent updates
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Aug 20Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Jul 26
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat
Nov 09Denali Therapeutics proposes $250M stock offering; shares down 6% post market
Oct 18Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Oct 12Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
Oct 10We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Jun 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$427m |
| Jun 30 2024 | n/a | n/a | -US$420m |
| Mar 31 2024 | n/a | n/a | -US$137m |
| Dec 31 2023 | US$8m | US$670k | -US$145m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$128m |
| Mar 31 2023 | n/a | n/a | -US$371m |
| Dec 31 2022 | US$9m | US$645k | -US$326m |
| Sep 30 2022 | n/a | n/a | -US$303m |
| Jun 30 2022 | n/a | n/a | -US$284m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$13m | US$610k | -US$291m |
| Sep 30 2021 | n/a | n/a | US$30m |
| Jun 30 2021 | n/a | n/a | US$56m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$9m | US$589k | US$71m |
| Sep 30 2020 | n/a | n/a | -US$228m |
| Jun 30 2020 | n/a | n/a | -US$216m |
| Mar 31 2020 | n/a | n/a | -US$215m |
| Dec 31 2019 | US$5m | US$567k | -US$198m |
| Sep 30 2019 | n/a | n/a | -US$66m |
| Jun 30 2019 | n/a | n/a | -US$55m |
| Mar 31 2019 | n/a | n/a | -US$52m |
| Dec 31 2018 | US$6m | US$545k | -US$36m |
| Sep 30 2018 | n/a | n/a | -US$137m |
| Jun 30 2018 | n/a | n/a | -US$123m |
| Mar 31 2018 | n/a | n/a | -US$91m |
| Dec 31 2017 | US$1m | US$481k | -US$88m |
Compensation vs Market: Ryan's total compensation ($USD7.88M) is about average for companies of similar size in the US market ($USD6.54M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
CEO
Ryan Watts (48 yo)
9.3yrs
Tenure
US$7,879,267
Compensation
Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.3yrs | US$7.88m | 1.56% $ 54.9m | |
| Co-Founder | 9.7yrs | US$4.17m | 0.41% $ 14.3m | |
| Co-Founder & Independent Director | no data | US$431.93k | 1.47% $ 51.7m | |
| Chief Medical Officer & Head of Development | 9.4yrs | US$4.17m | 0.14% $ 5.1m | |
| Senior Vice President of Corporate Finance | no data | no data | no data | |
| Chief Technical and Manufacturing Officer | 6.3yrs | no data | no data | |
| Chief Scientific Officer | 4.3yrs | no data | no data | |
| Vice President of Investor Relations | 4.8yrs | no data | no data | |
| General Counsel | 5.8yrs | no data | no data | |
| Vice President of Corporate Development | 1.8yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Commercial Officer | 3.2yrs | no data | no data |
5.8yrs
Average Tenure
51yo
Average Age
Experienced Management: DNLI's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.7yrs | US$7.88m | 1.56% $ 54.9m | |
| Co-Founder & Independent Director | 9.7yrs | US$431.93k | 1.47% $ 51.7m | |
| Independent Chairperson | 9.6yrs | US$459.43k | 0.073% $ 2.6m | |
| Independent Director | 9.6yrs | US$444.43k | 0.24% $ 8.3m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.6yrs | US$439.43k | 0.042% $ 1.5m | |
| Member of Scientific Advisory Board | 4yrs | no data | no data | |
| Independent Director | 6.7yrs | US$439.43k | 0.011% $ 380.5k | |
| Independent Director | 6yrs | US$429.43k | 0.0098% $ 344.9k | |
| Director | 2.5yrs | US$419.43k | 0.57% $ 20.3m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
8.1yrs
Average Tenure
64yo
Average Age
Experienced Board: DNLI's board of directors are considered experienced (8.1 years average tenure).